Josep M Argils

List of Publications by Citations

190 papers	13,112 citations	60 h-index	109 g-index
195 ext. papers	14,854 ext. citations	5.8 avg, IF	6.14 L-index

#	Paper	IF	Citations
190	Cachexia: a new definition. *Clinical Nutrition*, **2008**, 27, 793-9	5.9	1486
189	Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". *Clinical Nutrition*, **2010**, 29, 154-9	5.9	1075
188	Cancer cachexia: understanding the molecular basis. *Nature Reviews Cancer*, **2014**, 14, 754-62	31.3	662
187	Sarcopenia with limited mobility: an international consensus. *Journal of the American Medical Directors Association*, **2011**, 12, 403-9	5.9	648
186	Nutritional recommendations for the management of sarcopenia. *Journal of the American Medical Directors Association*, **2010**, 11, 391-6	5.9	387
185	Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. *Biochemical and Biophysical Research Communications*, **1999**, 254, 739-43	3.4	220
184	Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease. *Journal of the American Medical Directors Association*, **2016**, 17, 789-96	5.9	199
183	Cachexia and sarcopenia: mechanisms and potential targets for intervention. *Current Opinion in Pharmacology*, **2015**, 22, 100-6	5.1	178
182	Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. *American Journal of Physiology - Endocrinology and Metabolism*, **2009**, 296, E191-202	6	167
181	Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. *Experimental Cell Research*, **2002**, 280, 55-63	4.2	158
180	The role of cytokines in cancer cachexia. *Medicinal Research Reviews*, **1999**, 19, 223-48	14.4	154
179	TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. *Biochemical and Biophysical Research Communications*, **1997**, 230, 238-41	3.4	143
178	The role of cytokines in cancer cachexia. *Current Opinion in Supportive and Palliative Care*, **2009**, 3, 263-8	2.6	142
177	Cross-talk between skeletal muscle and adipose tissue: a link with obesity?. *Medicinal Research Reviews*, **2005**, 25, 49-65	14.4	132
176	Reduced muscle redox capacity after endurance training in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2001**, 164, 1114-8	10.2	132
175	The metabolic basis of cancer cachexia. *Medicinal Research Reviews*, **1997**, 17, 477-98	14.4	131
174	Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. *Cancer Research*, **2004**, 64, 6725-31	10.1	131

173	Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. *Biochimica Et Biophysica Acta - General Subjects*, **2001**, 1526, 17-24	4	128
172	Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. *Cell Biology International*, **2005**, 29, 449-57	4.5	126
171	IGF-1 is downregulated in experimental cancer cachexia. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2006**, 291, R674-83	3.2	124
170	Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. *European Respiratory Journal*, **2003**, 21, 789-94	13.6	123
169	Metabolic effects of tumour necrosis factor-alpha (cachectin) and interleukin-1. *Clinical Science*, **1989**, 77, 357-64	6.5	123
168	Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. *International Journal of Biochemistry and Cell Biology*, **2005**, 37, 1084-104	5.6	118
167	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. *European Heart Journal*, **2014**, 35, 932-41	9.5	117
166	Tumour necrosis factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. *FEBS Letters*, **1993**, 323, 211-4	3.8	116
165	Journey from cachexia to obesity by TNF. *FASEB Journal*, **1997**, 11, 743-51	0.9	111
164	The cachexia score (CASCO): a new tool for staging cachectic cancer patients. *Journal of Cachexia, Sarcopenia and Muscle*, **2011**, 2, 87-93	10.3	109
163	Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. *FEBS Letters*, **1994** , 338, 311-8	3.8	107
162	Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. *International Journal of Cancer*, **1995**, 61, 138-41	7.5	98
161	Inter-tissue communication in cancer cachexia. *Nature Reviews Endocrinology*, **2018**, 15, 9-20	15.2	97
160	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. *Journal of Cachexia, Sarcopenia and Muscle*, **2012**, 3, 37-43	10.3	94
159	Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. *Molecular and Cellular Endocrinology*, **1998**, 142, 183-9	4.4	94
158	Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. *FEBS Letters*, **2005**, 579, 1646-52	3.8	93
157	Cytokines in the pathogenesis of cancer cachexia. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2003**, 6, 401-6	3.8	93
156	Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. *Cancer Letters*, **1998**, 133, 83-7	9.9	92

155	Are there any benefits of exercise training in cancer cachexia?. *Journal of Cachexia, Sarcopenia and Muscle*, **2012**, 3, 73-6	10.3	91
154	DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia?. *Biochemical and Biophysical Research Communications*, **2000**, 270, 533-7	3.4	87
153	Myostatin: more than just a regulator of muscle mass. *Drug Discovery Today*, **2012**, 17, 702-9	8.8	85
152	Cancer cachexia: the molecular mechanisms. *International Journal of Biochemistry and Cell Biology*, **2003**, 35, 405-9	5.6	85
151	Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. *FEBS Letters*, **2004**, 569, 201-6	3.8	81
150	In the rat, tumor necrosis factor alpha administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis?. *FEBS Letters* , **1998**, 440, 348-50	3.8	80
149	The role of uncoupling proteins in pathophysiological states. *Biochemical and Biophysical Research Communications*, **2002**, 293, 1145-52	3.4	80
148	Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. *Cancer Letters*, **2001**, 167, 33-8	9.9	76
147	The pivotal role of cytokines in muscle wasting during cancer. *International Journal of Biochemistry and Cell Biology*, **2005**, 37, 2036-46	5.6	75
146	The role of cytokines in muscle wasting: its relation with cancer cachexia. *Medicinal Research Reviews*, **1992**, 12, 637-52	14.4	74
145	Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. *Nutrition*, **2005**, 21, 977-85	4.8	73
144	Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. *Biochimica Et Biophysica Acta - General Subjects*, **2002**, 1570, 33-7	4	73
143	Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. *International Journal of Oncology*, **2013**, 43, 886-94	4.4	71
142	Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?. *Biochimica Et Biophysica Acta - General Subjects*, **2013**, 1830, 2770-8	4	70
141	Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. *Obesity*, **2011**, 19, 362-9	8	68
140	Anti-tumour necrosis factor-alpha treatment interferes with changes in lipid metabolism in a tumour cachexia model. *Clinical Science*, **1994**, 87, 349-55	6.5	66
139	Central melanin-concentrating hormone influences liver and adipose metabolism via specific hypothalamic nuclei and efferent autonomic/JNK1 pathways. *Gastroenterology*, **2013**, 144, 636-649.e6	13.3	64
138	Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. *Journal of Cachexia, Sarcopenia and Muscle*, **2011**, 2, 95-104	10.3	63

137	Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. *Cancer Letters*, **1998**, 130, 19-27	9.9	63
136	The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. *Trends in Pharmacological Sciences*, **1996**, 17, 223-6	13.2	63
135	Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. *Oncotarget*, **2015**, 6, 43202-15	3.3	63
134	Redox balance and carbonylated proteins in limb and heart muscles of cachectic rats. *Antioxidants and Redox Signaling*, **2010**, 12, 365-80	8.4	62
133	Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine. *Biochimica Et Biophysica Acta - General Subjects*, **2006**, 1760, 1613-7	4	61
132	Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. *FEBS Letters*, **1998**, 436, 415-8	3.8	60
131	Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. *Cancer Letters*, **2007**, 245, 144-8	9.9	60
130	Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. *Oncology Reports*, **2005**, 14, 257-63	3.5	58
129	Cachexia: a problem of energetic inefficiency. *Journal of Cachexia, Sarcopenia and Muscle*, **2014**, 5, 279-86	10.3	56
128	Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. *International Journal of Molecular Medicine*, **2011**, 27, 15-24	4.4	56
127	Anti-inflammatory therapies in cancer cachexia. *European Journal of Pharmacology*, **2011**, 668 Suppl 1, S81-6	5.3	55
126	Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. *Clinical Nutrition*, **2007**, 26, 614-8	5.9	54
125	Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. *Journal of Cellular Physiology*, **2000**, 184, 380-4	7	53
124	Tumor necrosis factor-alpha exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2002**, 1542, 66-72	4.9	52
123	Novel approaches to the treatment of cachexia. *Drug Discovery Today*, **2008**, 13, 73-8	8.8	50
122	Catabolic proinflammatory cytokines. *Current Opinion in Clinical Nutrition and Metabolic Care*, **1998**, 1, 245-51	3.8	50
121	Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. *International Journal of Molecular Medicine*, **2005**, 16, 471-6	4.4	50
120	Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. *Drug Discovery Today*, **2009**, 14, 208-13	8.8	48

119	Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario. *Seminars in Cell and Developmental Biology*, **2016**, 54, 20-7	7.5	47
118	Muscle wasting in cancer: the role of mitochondria. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2015**, 18, 221-5	3.8	46
117	Counteracting inflammation: a promising therapy in cachexia. *Critical Reviews in Oncogenesis*, **2012**, 17, 253-62	1.3	46
116	Training depletes muscle glutathione in patients with chronic obstructive pulmonary disease and low body mass index. *Respiration*, **2006**, 73, 757-61	3.7	46
115	Novel targeted therapies for cancer cachexia. *Biochemical Journal*, **2017**, 474, 2663-2678	3.8	45
114	Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. *FEBS Letters*, **2005**, 579, 717-22	3.8	45
113	Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). *Cancer Letters*, **1995**, 95, 33-8	9.9	45
112	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β2 agonist. *International Journal of Cancer*, **2016**, 138, 2021-9	7.5	44
111	Cytokines as mediators and targets for cancer cachexia. *Cancer Treatment and Research*, **2006**, 130, 199-217	3.5	44
110	Optimal management of cancer anorexia-cachexia syndrome. *Cancer Management and Research*, **2010**, 2, 27-38	3.6	43
109	Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)C]-triolein load. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2006**, 1761, 37-42	5	43
108	Interleukin-6 does not activate protein breakdown in rat skeletal muscle. *Cancer Letters*, **1994**, 76, 1-4	9.9	43
107	Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. *International Journal of Cancer*, **2012**, 131, 2187-96	7.5	42
106	Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth. *Cancer Letters*, **1997**, 115, 113-8	9.9	42
105	Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function. *Journal of Molecular Biology*, **2019**, 431, 2674-2686	6.5	41
104	Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. *International Journal of Biochemistry and Cell Biology*, **2008**, 40, 1674-8	5.6	39
103	The pharmacological treatment of cachexia. *Current Drug Targets*, **2004**, 5, 265-77	3	39
102	Potassium channels are a new target field in anticancer drug design. *Recent Patents on Anti-Cancer Drug Discovery*, **2007**, 2, 212-23	2.6	38

101	Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists. *Cancer Research*, **2007**, 67, 6512-9	10.1	38
100	Mechanisms to explain wasting of muscle and fat in cancer cachexia. *Current Opinion in Supportive and Palliative Care*, **2007**, 1, 293-8	2.6	38
99	Catabolic mediators as targets for cancer cachexia. *Drug Discovery Today*, **2003**, 8, 838-44	8.8	38
98	Conversion of leucine to □hydroxy-□methylbutyrate by □keto isocaproate dioxygenase is required for a potent stimulation of protein synthesis in L6 rat myotubes. *Journal of Cachexia, Sarcopenia and Muscle*, **2016**, 7, 68-78	10.3	38
97	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. *Journal of Cachexia, Sarcopenia and Muscle*, **2016**, 7, 48-59	10.3	37
96	Mechanisms and treatment of cancer cachexia. *Nutrition, Metabolism and Cardiovascular Diseases*, **2013**, 23 Suppl 1, S19-24	4.5	36
95	Nonmuscle Tissues Contribution to Cancer Cachexia. *Mediators of Inflammation*, **2015**, 2015, 182872	4.3	36
94	Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. *Clinical Nutrition*, **2007**, 26, 239-44	5.9	36
93	Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. *Cytokine*, **2003**, 22, 1-4	4	36
92	Leptin and tumor growth in rats. *International Journal of Cancer*, **1999**, 81, 726-9	7.5	36
91	Effects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARs. *Obesity*, **2008**, 16, 285-9	8	35
90	The pivotal role of cytokines in muscle wasting during cancer. *International Journal of Biochemistry and Cell Biology*, **2005**, 37, 1609-19	5.6	35
89	Branched-chain amino acids: a role in skeletal muscle proteolysis in catabolic states?. *Journal of Cellular Physiology*, **2002**, 191, 283-9	7	35
88	Formoterol in the treatment of experimental cancer cachexia: effects on heart function. *Journal of Cachexia, Sarcopenia and Muscle*, **2014**, 5, 315-20	10.3	33
87	Mediators of cachexia in cancer patients. *Nutrition*, **2019**, 66, 11-15	4.8	32
86	Accounting information and the prediction of farm non-viability. *European Accounting Review*, **2001**, 10, 73-105	2.1	32
85	Effects of the beta agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia. *Biochimie*, **2018**, 149, 79-91	4.6	31
84	Cancer cachexia: physical activity and muscle force in tumour-bearing rats. *Oncology Reports*, **2011**, 25, 189-93	3.5	31

83	TNF-alpha modulates cytokine and cytokine receptors in C2C12 myotubes. *Cancer Letters*, **2002**, 175, 181-5	9.9	30
82	Short-term effects of leptin on skeletal muscle protein metabolism in the rat. *Journal of Nutritional Biochemistry*, **2000**, 11, 431-5	6.3	30
81	The potential of ghrelin in the treatment of cancer cachexia. *Expert Opinion on Biological Therapy*, **2013**, 13, 67-76	5.4	29
80	A new look at an old drug for the treatment of cancer cachexia: megestrol acetate. *Clinical Nutrition* , **2013**, 32, 319-24	5.9	29
79	L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. *Clinical Nutrition*, **2012**, 31, 889-95	5.9	29
78	Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. *Frontiers in Physiology*, **2017**, 8, 92	4.6	28
77	Roles of skeletal muscle and peroxisome proliferator-activated receptors in the development and treatment of obesity. *Endocrine Reviews*, **2006**, 27, 318-29	27.2	28
76	The use of financial accounting information and firm performance: an empirical quantification for farms. *Accounting and Business Research*, **2003**, 33, 251-273	1.9	28
75	Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?. *FEBS Letters*, **2001**, 505, 255-8	3.8	28
74	Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. *Cancer Letters*, **1996**, 99, 7-14	9.9	28
73	Therapeutic strategies against cancer cachexia. *European Journal of Translational Myology*, **2019**, 29, 7960	2.1	27
72	Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. *Oncology Letters*, **2012**, 3, 185-189	2.6	27
71	UCP3 overexpression neutralizes oxidative stress rather than nitrosative stress in mouse myotubes. *FEBS Letters*, **2009**, 583, 350-6	3.8	25
70	Lipid metabolism in tumour-bearing mice: studies with knockout mice for tumour necrosis factor receptor 1 protein. *Molecular and Cellular Endocrinology*, **1997**, 132, 93-9	4.4	25
69	Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. *Cancer Letters*, **1995**, 91, 73-8	9.9	24
68	Short-term effects of leptin on lipid metabolism in the rat. *FEBS Letters*, **1998**, 431, 371-4	3.8	23
67	The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. *FEBS Letters*, **2006**, 580, 691-6	3.8	23
66	Interleukin-15 affects differentiation and apoptosis in adipocytes: implications in obesity. *Lipids*, **2011**, 46, 1033-42	1.6	22

65	Is TNF really involved in cachexia?. *Cancer Investigation*, **1997**, 15, 47-54	2.1	22
64	Antiproteolytic effects of plasma from hibernating bears: a new approach for muscle wasting therapy?. *Clinical Nutrition*, **2007**, 26, 658-61	5.9	22
63	Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3. *PLoS ONE*, **2014**, 9, e113931	3.7	22
62	Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?. *Journal of Cachexia, Sarcopenia and Muscle*, **2011**, 2, 57-62	10.3	21
61	Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia. *Clinical Nutrition*, **2010**, 29, 733-7	5.9	21
60	The systemic inflammatory response is involved in the regulation of K(+) channel expression in brain via TNF-alpha-dependent and -independent pathways. *FEBS Letters*, **2004**, 572, 189-94	3.8	21
59	Increased uncoupling protein-2 gene expression in brain of lipopolysaccharide-injected mice: role of tumour necrosis factor-alpha?. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2001**, 1499, 249-56	4.9	21
58	Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth. *Cancer Letters*, **1995**, 97, 25-32	9.9	21
57	Interleukin-15 increases calcineurin expression in 3T3-L1 cells: possible involvement on in vivo adipocyte differentiation. *International Journal of Molecular Medicine*, **2009**, 24, 453-8	4.4	20
56	Hypothalamic food intake regulation in a cancer-cachectic mouse model. *Journal of Cachexia, Sarcopenia and Muscle*, **2014**, 5, 159-69	10.3	19
55	Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. *Muscle and Nerve*, **2008**, 37, 190-5	3.4	17
54	Lipopolysaccharide (LPS) increases the in vivo oxidation of branched-chain amino acids in the rat: a cytokine-mediated effect. *Molecular and Cellular Biochemistry*, **1995**, 148, 9-15	4.2	17
53	Impaired voltage-gated K+ channel expression in brain during experimental cancer cachexia. *FEBS Letters*, **2003**, 536, 45-50	3.8	16
52	Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogene. *Cancer Letters*, **2003**, 200, 153-60	9.9	16
51	Lipid metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. *Molecular and Cellular Biochemistry*, **1996**, 165, 17-23	4.2	16
50	Targets in clinical oncology: the metabolic environment of the patient. *Frontiers in Bioscience - Landmark*, **2007**, 12, 3024-51	2.8	15
49	Metabolic interrelationships between liver and skeletal muscle in pathological states. *Life Sciences*, **2001**, 69, 1345-61	6.8	15
48	Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats. *PeerJ*, **2017**, 5, e4109	3.1	15

47	The 2015 ESPEN Sir David Cuthbertson lecture: Inflammation as the driving force of muscle wasting in cancer. *Clinical Nutrition*, **2017**, 36, 798-803	5.9	14
46	The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. *International Journal of Oncology*, **2007**, 30, 1239-45	1	14
45	Theophylline is able to partially revert cachexia in tumour-bearing rats. *Nutrition and Metabolism*, **2012**, 9, 76	4.6	13
44	Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. *Journal of Lipid Research*, **2013**, 54, 3045-51	6.3	13
43	Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. *Experimental and Therapeutic Medicine*, **2011**, 2, 731-735	2.1	13
42	Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: a role in muscle wasting?. *Biochimica Et Biophysica Acta - General Subjects*, **2006**, 1760, 253-8	4	13
41	A flow cytometric study of the rat Yoshida AH-130 ascites hepatoma. *Cancer Letters*, **1993**, 72, 169-73	9.9	13
40	Rat liver lipogenesis is modulated by interleukin-15. *International Journal of Molecular Medicine*, **2004**, 13, 817-9	4.4	13
39	Cancer cachexia, a clinical challenge. *Current Opinion in Oncology*, **2019**, 31, 286-290	4.2	12
38	A Rat Immobilization Model Based on Cage Volume Reduction: A Physiological Model for Bed Rest?. *Frontiers in Physiology*, **2017**, 8, 184	4.6	11
37	A differential pattern of gene expression in skeletal muscle of tumor-bearing rats reveals dysregulation of excitation□contraction coupling together with additional muscle alterations. *Muscle and Nerve*, **2014**, 49, 233-48	3.4	11
36	Accounting Research: A Critical View Of The Present Situation And Prospects. *Revista De Contabilidad-Spanish Accounting Review*, **2011**, 14, 9-34	1.3	10
35	Sequential changes in lipoprotein lipase activity and lipaemia induced by the Yoshida AH-130 ascites hepatoma in rats. *Cancer Letters*, **1997**, 116, 159-65	9.9	10
34	Metabolic effects of tumour necrosis factor-alpha on rat brown adipose tissue. *Molecular and Cellular Biochemistry*, **1995**, 143, 113-8	4.2	10
33	Sepsis induces DNA fragmentation in rat skeletal muscle. *European Cytokine Network*, **2003**, 14, 256-9	3.3	10
32	Alanine metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. *Cancer Letters*, **1994**, 87, 123-30	9.9	9
31	Both AP-1 and NF-kappaB seem to be involved in tumour growth in an experimental rat hepatoma. *Anticancer Research*, **2009**, 29, 1315-7	2.3	9
30	Unifying diagnostic criteria for cachexia: An urgent need. *Clinical Nutrition*, **2017**, 36, 910-911	5.9	8

29	Fair value versus historical cost-based valuation for biological assets: predictability of financial information. *Revista De Contabilidad-Spanish Accounting Review*, **2011**, 14, 87-113	1.3	8
28	Formoterol May Activate Rat Muscle Regeneration During Cancer Cachexia. *Insciences Journal*,1-17		8
27	Nutraceutical inhibition of muscle proteolysis: a role of diallyl sulphide in the treatment of muscle wasting. *Clinical Nutrition*, **2011**, 30, 33-7	5.9	7
26	Protein breakdown on whole-body and organ level in non-cachectic tumour-bearing mice undergoing surgery. *Clinical Nutrition*, **2007**, 26, 483-90	5.9	7
25	Interleukin-15 decreases lipid intestinal absorption. *International Journal of Molecular Medicine*, **2005**, 15, 963-7	4.4	7
24	The ubiquitin system: a role in disease?. *Medicinal Research Reviews*, **1997**, 17, 139-61	14.4	6
23	Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy. *Biochimica Et Biophysica Acta - General Subjects*, **2007**, 1770, 1028-36	4	6
22	Emerging drugs for cancer cachexia. *Expert Opinion on Emerging Drugs*, **2007**, 12, 555-70	3.7	6
21	Effects of formoterol on protein metabolism in myotubes during hyperthermia. *Muscle and Nerve*, **2011**, 43, 268-73	3.4	5
20	Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats. *Journal of Cellular Physiology*, **2020**, 235, 526-537	7	5
19	Patterns of gene expression in muscle and fat in tumor-bearing rats: effects of CRF2R agonist on cachexia. *Muscle and Nerve*, **2010**, 42, 936-49	3.4	4
18	The Role of Cytokines in Cancer Cachexia **2006**, 467-475		4
17	The animal cachexia score (ACASCO). *Animal Models and Experimental Medicine*, **2019**, 2, 201-209	4.2	3
16	Cancer Cachexia **2013**,		3
15	Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. *E-SPEN Journal*, **2012**, 7, e135-e138		3
14	Open source in cachexia?. *Journal of Cachexia, Sarcopenia and Muscle*, **2015**, 6, 112-3	10.3	2
13	Cancer Cachexia and Fat Metabolism **2006**, 459-466		2
12	Les facteurs cataboliques du cancer : donnÉes rÉcentes. *Nutrition Clinique Et Metabolisme*, **2002**, 16, 14-25	0.8	2

11	Marked hyperlipidaemia in rats bearing the Yoshida AH-130 ascites hepatoma. *Biochemical Society Transactions*, **1995**, 23, 492S	5.1	2
10	Omega-3 and omega-3/curcumin-enriched fruit juices decrease tumour growth and reduce muscle wasting in tumour-bearing mice. *JCSM Rapid Communications*, **2018**, 1, 1-10	2.6	2
9	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.. *International Journal of Molecular Medicine*, **2004**, 14, 719	4.4	1
8	Cross-Talk Between Skeletal Muscle and Adipose Tissue: A Link with Obesity?. *ChemInform*, **2005**, 36, no		1
7	Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. *Cancer Letters*, **2002**, 188, 53-8	9.9	1
6	Recent Developments in Treatment of Cachexia. *AAPS Advances in the Pharmaceutical Sciences Series*, **2014**, 259-273	0.5	1
5	Muscle Wasting in Cancer and Ageing: Cachexia Versus Sarcopenia **2011**, 9-35		1
4	Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes. *JCSM Rapid Communications*, **2018**, 1, 1-15	2.6	1
3	Lack of Synergy Between β-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model. *OncoTargets and Therapy*, **2021**, 14, 1953-1959	4.4	0
2	Latest developments in cachexia drug discovery: clinical trials **2013**, 46-61		
1	Cancer cachexia **2013**, 2-5		